This page documents emerging biotechnology companies (founded 2020-2025) developing novel Alzheimer's disease therapeutics targeting mechanisms beyond traditional amyloid-beta and tau approaches. These companies represent the next generation of AD drug development, focusing on neuroinflammation, mitochondrial dysfunction, synaptic protection, cellular senescence, and precision medicine approaches["@next"].
| Attribute | Value |
|-----------|-------|
| Founded | 2017 |
| Headquarters | London, UK / Cambridge, MA |
| Ticker | Private |
| Mechanism | NLRP3 inflammasome inhibition |
Nodthera develops first-in-class small molecule inhibitors of the NLRP3 inflammasome, a key driver of chronic neuroinflammation in Alzheimer's disease. Their lead candidate NT-0796 is in Phase 1/2 trials for AD[@nodthera].
| Attribute | Value |
|-----------|-------|
| Founded | 2020 |
| Headquarters | Cambridge, MA |
| Ticker | Private |
| Mechanism | TREM2 agonist |
Vigil Neuroscience focuses on targeting TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), a receptor on microglia that regulates the brain's immune response. Loss of TREM2 function is linked to increased AD risk[@vigil].
| Attribute | Value |
|-----------|-------|
| Founded | 2020 |
| Headquarters | San Francisco, CA |
| Ticker | NASDAQ: ABOS |
| Mechanism | TREM2 antibody |
Acumen develops TREM2-targeting antibodies to enhance microglial function and clear amyloid deposits. Their lead candidate AC-001 is in Phase 1 trials[@acumen].
| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | Geneva, Switzerland |
| Ticker | Private |
| Mechanism | Mitochondrial quality control |
Vandria targets mitochondrial dysfunction, a fundamental contributor to neuronal death in Alzheimer's disease. Their lead program VNA-318 is a small molecule mitochondrial modulator in Phase 1[@vandria].
| Attribute | Value |
|-----------|-------|
| Founded | 2021 |
| Headquarters | Cambridge, MA |
| Ticker | Private |
| Mechanism | Synaptic protection and restoration |
Synaptic Therapeutics focuses on protecting and restoring synaptic function, the strongest pathological correlate of cognitive decline in AD. Their approach targets synaptic plasticity enhancers[@synaptic].
| Attribute | Value |
|-----------|-------|
| Founded | 2019 |
| Headquarters | Seattle, WA |
| Ticker | NASDAQ: ATHA |
| Mechanism | HGF/MET agonist |
Athira develops fosgonimeton (ATH-1017), a small molecule that activates the HGF/MET signaling pathway, promoting neuroprotection, synaptic plasticity, and cognitive function[@athira].
| Attribute | Value |
|-----------|-------|
| Founded | 2022 |
| Headquarters | San Francisco, CA |
| Ticker | Private |
| Mechanism | Senolytic, autophagy modulation |
Retro Biosciences targets cellular senescence and protein homeostasis, two hallmarks of aging directly relevant to neurodegenerative disease. Their senolytic RB-001 is in Phase 1 for AD[@retro].
| Attribute | Value |
|-----------|-------|
| Founded | 2020s |
| Headquarters | Boston, MA |
| Ticker | Private |
| Mechanism | NLRP3 inhibitor, anti-inflammatory |
Lyterian develops LYT-100, a NLRP3 inflammasome inhibitor in Phase 1b/2a trials for AD. The company focuses on chronic neuroinflammation as a driver of neurodegeneration[@lyterian].
| Attribute | Value |
|-----------|-------|
| Founded | 2020 |
| Headquarters | South San Francisco, CA |
| Ticker | Private |
| Mechanism | Precision medicine, AI-driven target selection |
Neuron23 combines data science, human genetics, and clinical approaches to develop precision medicines for genetically defined neurological diseases. Their pipeline includes programs targeting specific genetic subtypes of AD and PD[@neuron].
| Attribute | Value |
|-----------|-------|
| Founded | 2013 |
| Headquarters | Salt Lake City, UT |
| Ticker | NASDAQ: RXRX |
| Mechanism | AI-driven drug discovery, phenotypic screening |
Recursion uses AI and high-throughput phenotypic screening to identify novel drug candidates for neurodegenerative diseases. Their approach maps genetic interactions to disease phenotypes[@recursion].
| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | South San Francisco, CA |
| Ticker | Private |
| Mechanism | Machine learning, stem cell models |
Insitro combines machine learning with human stem cell models to discover novel therapeutic targets and predict drug response. The company applies data-driven approaches to identify new AD targets[@insitro].
| Attribute | Value |
|-----------|-------|
| Founded | 2022 |
| Headquarters | San Francisco, CA |
| Ticker | Private |
| Mechanism | CNS drug delivery platform |
Koneqia addresses the critical challenge of CNS drug delivery that has hindered AD drug development. Their platform aims to enhance brain penetration of therapeutic molecules[@koneqia].
| Attribute | Value |
|-----------|-------|
| Founded | 2021 |
| Headquarters | Boston, MA |
| Ticker | Private |
| Mechanism | Engineered growth factors |
Trefoil develops engineered neurotrophic factors for CNS applications. Their platform creates optimized versions of growth factors that can protect and regenerate neurons[@trefoil].
| Company | Mechanism | Lead Program | Indication | Phase |
|---------|-----------|-------------|------------|-------|
| Nodthera | NLRP3 inhibitor | NT-0796 | AD | Phase 1/2 |
| Vigil Neuroscience | TREM2 agonist | VIG100 | AD | Preclinical |
| Acumen Pharmaceuticals | TREM2 antibody | AC-001 | AD | Phase 1 |
| Vandria | Mitochondrial modulator | VNA-318 | AD | Phase 1 |
| Synaptic Therapeutics | Synaptic protection | Preclinical | AD | Preclinical |
| Athira Pharma | HGF/MET agonist | fosgonimeton | AD | Phase 2/3 |
| Retro Biosciences | Senolytic | RB-001 | AD | Phase 1 |
| Lyterian | NLRP3 inhibitor | LYT-100 | AD | Phase 1b/2a |
| Neuron23 | Precision medicine | Preclinical | AD | Preclinical |
| Koneqia | CNS delivery | Platform | AD | Preclinical |
The emergence of these companies reflects a broader shift in AD drug development away from single-target amyloid approaches toward: